Нифурател-СЗ
 

Composition
1 tablet contains:

active ingredient:

nifuratel - 200 mg;

excipients: corn starch - 90.7 mg, gelatin -2.3 mg, polyethyleneglycol 6000 (macrogol) - 15.0 mg, talc - 9.0 mg; magnesium stearate - 3.0 mg;

shell composition: hypromellose - 5.37 mg, polysorbate-80 (tween-80) - 1.50 mg, talc - 1.50 mg, titanium dioxide E 171 - 1.13 mg, aluminum lake based on quinoline yellow dye - 0.50 mg.

Pharmacological action
Pharmacological action - antimicrobial, antiprotozoal, antifungal.

Pharmacodynamics
Nifuratel is an antimicrobial agent from the nitrofuran group, has antiprotozoal, antifungal and antibacterial effects.

Nifuratel has high efficiency and low toxicity, which determines its wide range of clinical application.

Highly effective against Papiliobacter and Helicobacter pylori, gram-positive and gram-negative microorganisms.

The spectrum of action includes: Enterococcus faecalis, Enterococcus faecium, Staphylococcus aureus, Bacillus subtilis, Escherichia coli, Shigella flexneri 2a, Shigella flexneri 6, Shigella sonnei, Salmonella typhi, Salmonella typhimurium, Salmonella enteridis, Klebsiella spp., Enterobacter spp., Serratia spp., Citrobacter spp., Morganella spp., Rettgerella spp., Pragia fontium, Budvicia aquatica, Rachnella aquatilis and Acinetobacter spp., other atypical enterobacteria, as well as protozoa (Trichomonas, amoebas, lamblia); less active against Proteus mirabilis, Proteus vulgaris, Pseudomonas aeruginosa. It is the drug of choice for the treatment of salmonellosis, shigellosis and other acute intestinal bacterial infections.

It is active against Trichomonas vaginalis, highly active against Candida fungi.

It is especially effective against Helicobacter pylori strains resistant to metronidazole.

Pharmacokinetics

When taken orally, it is quickly absorbed from the gastrointestinal tract. It penetrates the blood-brain barrier and the gastro-intestinal barrier, and is excreted in breast milk. It is metabolized in the liver and muscle tissue. It is completely excreted from the body by the kidneys (30–50% unchanged), exerting a strong antibacterial effect in the urinary tract.

Indications
Vulvovaginal infections caused by pathogens sensitive to the drug (pathogenic microorganisms, Candida fungi, trichomonads, bacteria, chlamydia).
Pyelonephritis, urethritis, cystitis, pyelitis and other diseases of the urinary system.
Intestinal amebiasis and giardiasis.
Chronic inflammatory diseases of the upper gastrointestinal tract associated with Helicobacter pylori infection.
Use during pregnancy and breastfeeding
Pregnancy

When administered orally, nufuratel does not have a teratogenic effect in preclinical studies on mice, rats and rabbits.

There are no clinical studies in pregnant women. It is not recommended to use the drug during pregnancy. The drug should be prescribed only under the supervision of a doctor after a thorough assessment of the benefits versus the possible risk.

Nifuratel penetrates the HPB, so the use of the drug is possible only for strict indications, if the expected effect of therapy for the mother exceeds the potential risk to the fetus. If pregnancy is suspected, it is recommended to consult a doctor.

Breastfeeding

Nifuratel is excreted in breast milk, so if it is necessary to prescribe the drug during breastfeeding, the issue of stopping breastfeeding should be resolved.

Contraindications
Hypersensitivity to the active substance or any component of the drug.

Children under 3 years of age and weighing less than 20 kg.
Side effects
Dyspeptic disorders: nausea, vomiting, bitterness in the mouth, diarrhea, heartburn.

Allergic reactions: skin rash, itching.
Interaction
Enhances the antifungal effect of nystatin.
How to take, course of administration and dosage
Orally, following the recommendations.

Vaginal infections

Adults: 1 tablet 3 times a day after meals for 7 days (both sexual partners should take the drug).

Children over 3 years old and weighing more than 20 kg. The recommended dose is 10 mg / kg daily for 10 days. The recommended dose should be taken in two doses.

Urinary tract infections

Adults: depending on the severity of the disease, 1-2 tablets 3 times a day for 7-14 days.

Children over 3 years old and weighing more than 20 kg: The recommended dose is 30-60 mg / kg. The recommended dose should be taken in two doses.

On the recommendation of a doctor, the course of treatment for urinary tract infections can be extended or repeated.

Intestinal amebiasis

Adults: 2 tablets 2-3 times a day for 10 days.

Children over 3 years of age and weighing over 20 kg: the recommended dose is 10 mg/kg 3 times a day.

Giardiasis

Adults: 2 tablets 2-3 times a day for 7 days.

Children over 3 years of age and weighing over 20 kg: the recommended dose is 15 mg/kg 2 times a day for 7 days.

Inflammatory diseases of the upper gastrointestinal tract associated with Helicobacter pylori

Adults: 2 tablets 2-3 times a day for 7 days.